From Baby Blues to Breakthroughs
Sage Therapeutics (SAGE) has been in the spotlight recently for biotechnology companies. With its recent rejection of Biogen's acquisition and FDA approval of one of its most recent Central Nervous System pharmaceuticals, Zurzuvae the firm has had an eventful timeline marked with opportunity. However, the biotech company has had major setbacks in the past seeing its stock pirce tank over 80% in the past 5 years its discontinuation of zulresso and the FDA not approving Zurzuvae for Major Depressive Disorder while also being prone to significant cash burn. Nonetheless, the company is selling at a historic discount and still demonstrates promising growth by reach a virtually untapped market by treating Post Partum Depression (PPD) with Zurzuvae.
Large TAM & Insurance Coverage
The number of women diagnosed with PPD every year around 600,000 and estimated to be significantly underdiagnosed. Thus, the number of women with formal diagnosis of this condition is growing rapidly and expected to increase at a CAGR of 3.8% through 2032 (Credence Research). This sizable consumer base is further reinforced by the sizeable insurance coverage that the drug has nationally. Costing just under $15,000 the medicine is relatively expensive to average consumers. However, 90% of Medicaid lives have some sort of coverage for the drug (SEC). Additionally, the 6 largest insurance firms: UnitedHealth Group, Kaiser Permanente, Elevance Health/Anthem, Health Care Service Corp. (Blue Cross Blue Shield IL/MT/NM/OK/TX), Centene, and CVS Health/Aetna all offer some form of coverage for Zurzuvae (goodrx).
Competitive Advantage
Typical treatment of PPD is an extremely time and energy intensive processs requiring in person evaluation of patients spanning over several weeks and months. Additionally, there has never been a pharmaceutical directly tailored towards PPD which has typically been treated with antipsychotics, and SSRIs. Fortunately, Sage has answered these problems with Zurzuvae as the small molecule compound only requires a 14 day treatment requiring just one pill a day minimizing time and energy spent treating the disorder. To further emphasize the efficacy of this drug, a Phase 3 trial saw 57% of patients treated with Zurzuvae experience significant symptom improvement after two weeks. The placeabo group on the other hand saw a 38% improvement. Thus, the treatment has statistically delivered positive results (brownhealth).